<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33255791</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2079-4991</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Nanomaterials (Basel, Switzerland)</Title><ISOAbbreviation>Nanomaterials (Basel)</ISOAbbreviation></Journal><ArticleTitle>Self-Assembled Multi-Epitope Peptide Amphiphiles Enhance the Immune Response against Enterovirus 71.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2342</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nano10122342</ELocationID><Abstract><AbstractText>Subunit vaccines consist of non-genetic material, such as peptides or proteins. They are considered safe because they have fewer side effects; however, they have low immunogenicity when used alone. We aimed to enhance the immune response of peptide-based vaccines by using self-assembled multimeric peptide amphiphiles (PAs). We designed two epitope PAs by conjugating epitope peptides from Enterovirus 71 (EV71) virus particle (VP) 1 and VP3 capsid proteins with different fatty acid chain lengths (VP1PA and VP3PA). These PAs self-assembled into supramolecular structures at a physiological pH, and the resulting structures were characterized using atomic force microscopy. Multi-epitope PAs (m-PAs) consisted of a 1:1 mixture of VP1PA and VP3PA solutions. To evaluate immunogenicity, m-PA constructs were injected with adjuvant subcutaneously into female Balb/c mice. Levels of antigen-specific immunoglobulin G (IgG) and IgG1 in m-PA-injected mice serum samples were analyzed using ELISA and Western blotting. Additionally, cytokine production stimulated by each antigen was measured in splenocytes cultured from immunized mice groups. We found that m-PA showed improved humoral and cellular immune responses compared to the control and peptide groups. The sera from m-PA immunized mice group could neutralize EV71 infection and protect host cells. Thus, self-assembled m-PAs can promote a protective immune response and can be developed as a potential platform technology to produce peptide vaccines against infectious viral diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yu-Gyeong</ForeName><Initials>YG</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Ajou University, Suwon 16499, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yunsu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Ajou University, Suwon 16499, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Joo Hee</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Ajou University, Suwon 16499, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Sun-Young</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0001-7336-9245</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, Ajou University, Suwon 16499, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Jong-Wha</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0001-9885-3447</Identifier><AffiliationInfo><Affiliation>Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu 41566, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Woo-Jae</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0001-6746-5599</Identifier><AffiliationInfo><Affiliation>Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Hyo-Eon</ForeName><Initials>HE</Initials><Identifier Source="ORCID">0000-0002-1292-5508</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, Ajou University, Suwon 16499, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute of Pharmaceutical Science and Technology, Ajou University, Suwon 16499, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HI17C0587</GrantID><Agency>the Korea Health Technology R&amp;D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &amp; Welfare, Republic of Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nanomaterials (Basel)</MedlineTA><NlmUniqueID>101610216</NlmUniqueID><ISSNLinking>2079-4991</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">immune stimulator</Keyword><Keyword MajorTopicYN="N">peptide amphiphile</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword><Keyword MajorTopicYN="N">viral infectious disease</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33255791</ArticleId><ArticleId IdType="pmc">PMC7760352</ArticleId><ArticleId IdType="doi">10.3390/nano10122342</ArticleId><ArticleId IdType="pii">nano10122342</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Plotkin S. History of vaccination. Proc. Natl. Acad. Sci. USA. 2014;111:12283&#x2013;12287. doi: 10.1073/pnas.1400472111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1400472111</ArticleId><ArticleId IdType="pmc">PMC4151719</ArticleId><ArticleId IdType="pubmed">25136134</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Global Vaccine Action Plan 2011&#x2013;2020. World Health Organization; Geneva, Switzerland: 2013.</Citation></Reference><Reference><Citation>Baxby D. Edward Jenner&#x2019;s inquiry after 200 years. BMJ. 1999;318:390. doi: 10.1136/bmj.318.7180.390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.318.7180.390</ArticleId><ArticleId IdType="pmc">PMC1114848</ArticleId><ArticleId IdType="pubmed">9933209</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup. Med. (Lond.) 2007;57:552&#x2013;556. doi: 10.1093/occmed/kqm110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/occmed/kqm110</ArticleId><ArticleId IdType="pubmed">18045976</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott C. Classifying vaccines.  [(accessed on 24 November 2020)];BioProcesses Int. 2004 :14&#x2013;23. Available online:  https://bioprocessintl.com/manufacturing/monoclonal-antibodies/chapter-2-classifying-vaccines-41200452/</Citation></Reference><Reference><Citation>Vartak A., Sucheck S.J. Recent advances in subunit vaccine carriers. Vaccines. 2016;4:12. doi: 10.3390/vaccines4020012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines4020012</ArticleId><ArticleId IdType="pmc">PMC4931629</ArticleId><ArticleId IdType="pubmed">27104575</ArticleId></ArticleIdList></Reference><Reference><Citation>Rold&#xe3;o A., Mellado M.C.M., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Expert Rev. Vaccines. 2010;9:1149&#x2013;1176. doi: 10.1586/erv.10.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.10.115</ArticleId><ArticleId IdType="pubmed">20923267</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudra J.S., Tian Y.F., Jung J.P., Collier J.H. A self-assembling peptide acting as an immune adjuvant. Proc. Natl. Acad. Sci. USA. 2010;107:622&#x2013;627. doi: 10.1073/pnas.0912124107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912124107</ArticleId><ArticleId IdType="pmc">PMC2818904</ArticleId><ArticleId IdType="pubmed">20080728</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder U., Graff A., Buchmeier S., Rigler P., Silvan U., Tropel D., Jockusch B.M., Aebi U., Burkhard P., Schoenenberger C.-A. Peptide nanoparticles serve as a powerful platform for the immunogenic display of poorly antigenic actin determinants. J. Mol. Biol. 2009;386:1368&#x2013;1381. doi: 10.1016/j.jmb.2008.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2008.11.023</ArticleId><ArticleId IdType="pubmed">19063898</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun M., Jandus C., Maurer P., Hammann-Haenni A., Schwarz K., Bachmann M.F., Speiser D.E., Romero P. Virus-like particles induce robust human T-helper cell responses. Eur. J. Immunol. 2012;42:330&#x2013;340. doi: 10.1002/eji.201142064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201142064</ArticleId><ArticleId IdType="pubmed">22057679</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita Y., Taguchi H. Micro and Nanotechnology in Vaccine Development. Elsevier; Amsterdam, The Netherlands: 2017. Nanoparticle-Based Peptide Vaccines; pp. 149&#x2013;170.</Citation></Reference><Reference><Citation>Jin H.E., Jang J., Chung J., Lee H.J., Wang E., Lee S.W., Chung W.J. Biomimetic Self-Templated Hierarchical Structures of Collagen-Like Peptide Amphiphiles. Nano Lett. 2015;15:7138&#x2013;7145. doi: 10.1021/acs.nanolett.5b03313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.nanolett.5b03313</ArticleId><ArticleId IdType="pubmed">26392232</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesauro D., Accardo A., Diaferia C., Milano V., Guillon J., Ronga L., Rossi F. Peptide-based drug-delivery systems in biotechnological applications: Recent advances and perspectives. Molecules. 2019;24:351. doi: 10.3390/molecules24020351.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24020351</ArticleId><ArticleId IdType="pmc">PMC6359574</ArticleId><ArticleId IdType="pubmed">30669445</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R., Smith J.D., Allen B.N., Kramer J.S., Schauflinger M., Ulery B.D. Peptide amphiphile micelle vaccine size and charge influence the host antibody response. ACS Biomater. Sci. Eng. 2018;4:2463&#x2013;2472. doi: 10.1021/acsbiomaterials.8b00511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsbiomaterials.8b00511</ArticleId><ArticleId IdType="pubmed">33435110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardo D., Kiselev M.A., Magaz&#xf9; S., Calandra P. Amphiphiles self-assembly: Basic concepts and future perspectives of supramolecular approaches. Adv. Condens. Matter Phys. 2015;2015:151683. doi: 10.1155/2015/151683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/151683</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachmann M.F., Jennings G.T. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010;10:787&#x2013;796. doi: 10.1038/nri2868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2868</ArticleId><ArticleId IdType="pubmed">20948547</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva G.A., Czeisler C., Niece K.L., Beniash E., Harrington D.A., Kessler J.A., Stupp S.I. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science. 2004;303:1352&#x2013;1355. doi: 10.1126/science.1093783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1093783</ArticleId><ArticleId IdType="pubmed">14739465</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.-G., Lee Y., Jung J.-W., Jin H.-E. Epitope Peptide Amphiphile-Based Nanofiber as an Effective Vaccine for Viral Infectious Diseases. J. Nanosci. Nanotechnol. 2020;20:5329&#x2013;5332. doi: 10.1166/jnn.2020.17655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1166/jnn.2020.17655</ArticleId><ArticleId IdType="pubmed">32331099</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudra J.S., Sun T., Bird K.C., Daniels M.D., Gasiorowski J.Z., Chong A.S., Collier J.H. Modulating adaptive immune responses to peptide self-assemblies. ACS Nano. 2012;6:1557&#x2013;1564. doi: 10.1021/nn204530r.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/nn204530r</ArticleId><ArticleId IdType="pmc">PMC3289747</ArticleId><ArticleId IdType="pubmed">22273009</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun H., Gao M., Cui D. Molecular Characteristics of VP1 Region of Enterovirus 71 Strains in China. Gut Pathog. 2020;12:38. doi: 10.1186/s13099-020-00377-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13099-020-00377-2</ArticleId><ArticleId IdType="pmc">PMC7427758</ArticleId><ArticleId IdType="pubmed">32818043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X., Ku Z., Liu Q., Wang X., Shi J., Zhang Y., Kong L., Cong Y., Huang Z. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J. Virol. 2014;88:72&#x2013;81. doi: 10.1128/JVI.01848-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01848-13</ArticleId><ArticleId IdType="pmc">PMC3911748</ArticleId><ArticleId IdType="pubmed">24131712</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L., Fan R., Sun S., Fan P., Su W., Zhou Y., Gao F., Xu F., Kong W., Jiang C. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice. Vaccine. 2015;33:6596&#x2013;6603. doi: 10.1016/j.vaccine.2015.10.104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.10.104</ArticleId><ArticleId IdType="pubmed">26529072</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi E.J., Shin Y.J., Kim J.H., Kim T.G., Chang S.Y. Enterovirus 71 infection and vaccines. Clin. Exp. Vaccine Res. 2017;6:4&#x2013;14. doi: 10.7774/cevr.2017.6.1.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2017.6.1.4</ArticleId><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.I., Song J.H., Kwon B.E., Kim H.N., Seo M.D., Park K., Lee S., Yeo S.G., Kweon M.N., Ko H.J., et al. Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection. Vaccine. 2015;33:6604&#x2013;6610. doi: 10.1016/j.vaccine.2015.10.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.10.103</ArticleId><ArticleId IdType="pubmed">26529069</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-azzawi S., Masheta D. Designing a drug delivery system for improved tumor treatment and targeting by functionalization of a cell-penetrating peptide. J. Pharm. Investig. 2019;49:643&#x2013;654. doi: 10.1007/s40005-018-00424-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40005-018-00424-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Hao C., Zhang S., Li A., Zhang Q., Wu W., Liu L., Li C., Liang M., Li X., et al. Oral immunization with recombinant enterovirus 71 VP1 formulated with chitosan protects mice against lethal challenge. Virol. J. 2014;11:80. doi: 10.1186/1743-422X-11-80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-11-80</ArticleId><ArticleId IdType="pmc">PMC4022980</ArticleId><ArticleId IdType="pubmed">24885121</ArticleId></ArticleIdList></Reference><Reference><Citation>Okur Z., Senturk O.I., Yilmaz C., Gulseren G., Mammadov B., Guler M.O., Tekinay A.B. Promotion of neurite outgrowth by rationally designed NGF-beta binding peptide nanofibers. Biomater. Sci. 2018;6:1777&#x2013;1790. doi: 10.1039/C8BM00311D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C8BM00311D</ArticleId><ArticleId IdType="pubmed">29770392</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H.J., Kim J.H., Lee C.H., Ahn Y.J., Song J.H., Baek S.H., Kwon D.H. Antiviral activity of quercetin 7-rhamnoside against porcine epidemic diarrhea virus. Antiviral. Res. 2009;81:77&#x2013;81. doi: 10.1016/j.antiviral.2008.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2008.10.002</ArticleId><ArticleId IdType="pmc">PMC7114206</ArticleId><ArticleId IdType="pubmed">18992773</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarajan R. Molecular packing parameter and surfactant self-assembly: The neglected role of the surfactant tail. Langmuir. 2002;18:31&#x2013;38. doi: 10.1021/la010831y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/la010831y</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper N.R., Nemerow G.R. The role of antibody and complement in the control of viral infections. J. Investig. Dermatol. 1984;83:121s&#x2013;127s. doi: 10.1038/jid.1984.33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jid.1984.33</ArticleId><ArticleId IdType="pubmed">6376646</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao R.Y., Dong D.Y., Liu R.J., Han J.F., Wang G.C., Zhao H., Li X.F., Deng Y.Q., Zhu S.Y., Wang X.Y., et al. Human IgG subclasses against enterovirus Type 71: Neutralization versus antibody dependent enhancement of infection. PLoS ONE. 2013;8:e64024. doi: 10.1371/journal.pone.0064024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064024</ArticleId><ArticleId IdType="pmc">PMC3659118</ArticleId><ArticleId IdType="pubmed">23700449</ArticleId></ArticleIdList></Reference><Reference><Citation>Malonis R.J., Lai J.R., Vergnolle O. Peptide-Based Vaccines: Current Progress and Future Challenges. Chem. Rev. 2020;120:3210&#x2013;3229. doi: 10.1021/acs.chemrev.9b00472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.9b00472</ArticleId><ArticleId IdType="pmc">PMC7094793</ArticleId><ArticleId IdType="pubmed">31804810</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Pasquale A., Preiss S., Tavares Da Silva F., Garcon N. Vaccine Adjuvants: From 1920 to 2015 and Beyond. Vaccines. 2015;3:320&#x2013;343. doi: 10.3390/vaccines3020320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines3020320</ArticleId><ArticleId IdType="pmc">PMC4494348</ArticleId><ArticleId IdType="pubmed">26343190</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hagan D.T., Ott G.S., Nest G.V., Rappuoli R., Giudice G.D. The history of MF59((R)) adjuvant: A phoenix that arose from the ashes. Expert Rev. Vaccines. 2013;12:13&#x2013;30. doi: 10.1586/erv.12.140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.12.140</ArticleId><ArticleId IdType="pubmed">23256736</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., van Hoogevest P., Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 1995;6:277&#x2013;296. doi: 10.1007/978-1-4615-1823-5_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4615-1823-5_10</ArticleId><ArticleId IdType="pubmed">7551221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan Y.F., Abubakar S. Enterovirus 71 infection induces apoptosis in Vero cells. Malays J. Pathol. 2003;25:29&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">16196375</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K., Nagata N., Sato Y., Ong K.C., Wong K.T., Yamayoshi S., Shimanuki M., Shitara H., Taya C., Koike S. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc. Natl. Acad. Sci. USA. 2013;110:14753&#x2013;14758. doi: 10.1073/pnas.1217563110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1217563110</ArticleId><ArticleId IdType="pmc">PMC3767555</ArticleId><ArticleId IdType="pubmed">23959904</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.-W., Yu S.-L., Shao H.-Y., Lin H.-Y., Liu C.-C., Hsiao K.-N., Chitra E., Tsou Y.-L., Chang H.-W., Sia C. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS ONE. 2013;8:e57591. doi: 10.1371/journal.pone.0057591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057591</ArticleId><ArticleId IdType="pmc">PMC3581494</ArticleId><ArticleId IdType="pubmed">23451246</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F., Yao P.-P., Xia Y., Qian L., Yang Z.-N., Xie R.-H., Sun Y.-S., Lu H.-J., Miao Z.-P., Li C. Enterovirus 71 infection causes severe pulmonary lesions in gerbils, meriones unguiculatus, which can be prevented by passive immunization with specific antisera. PLoS ONE. 2015;10:e0119173. doi: 10.1371/journal.pone.0119173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0119173</ArticleId><ArticleId IdType="pmc">PMC4359154</ArticleId><ArticleId IdType="pubmed">25767882</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y.-S., Li Y., Xia Y., Xu F., Wang W., Yang Z.-N., Lu H.-J., Chen Z.-P., Miao Z.-P., Liang W.-F. Coxsackievirus A16 induced neurological disorders in young gerbils which could serve as a new animal model for vaccine evaluation. Sci. Rep. 2016;6:1&#x2013;11. doi: 10.1038/srep34299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep34299</ArticleId><ArticleId IdType="pmc">PMC5035925</ArticleId><ArticleId IdType="pubmed">27667023</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>